The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Open accessAbstract
OBJECTIVE: To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard therapy in active systemic lupus erythematosus (SLE). METHODS: In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients with scores ≥6 on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) were randomized in a 1:1:1 ratio to receive 1 mg/kg belimumab, 10 mg/kg belimumab, or placebo intravenously on days 0, 14, and 28 and then every 28 days for 72 weeks. The primary efficacy end point was the SLE Responder Index (SRI) response rate at week 52 (an SRI response was defined as a ≥4-point reduction in SELENA-SLEDAI score, no new British Isles Lupus Assessment Group [BILAG] A organ domain score and no more than 1 new BILAG B score, and no worsening in physician's global assessment score versus baseline). RESULTS: Belimumab at 10 mg/kg plus standard therapy met the primary efficacy end point, generating a significantly greater SRI response at week 52 compared with placebo (43.2% versus 33.5%; P = 0.017). The rate with 1 mg/kg belimumab was 40.6% (P = 0.089). Response rates at week 76 were 32.4%, 39.1%, and 38.5% with placebo, 1 mg/kg belimumab, and 10 mg/kg belimumab, respectively. In post hoc sensitivity analyses evaluating higher SELENA-SLEDAI score thresholds, 10 mg/kg belimumab achieved better discrimination at weeks 52 and 76. Risk of severe flares over 76 weeks (based on the modified SLE Flare Index) was reduced with 1 mg/kg belimumab (34%) (P = 0.023) and 10 mg/kg belimumab (23%) (P = 0.13). Serious and severe adverse events, including infections, laboratory abnormalities, malignancies, and deaths, were comparable across groups. CONCLUSION: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationMortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Self-citationCombined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Self-citationBLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Self-citationCutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Self-citation(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
Avery, D. T., Kalled, S. L., Ellyard, J. I., Ambrose, C., Bixler, S. A., Thien, M., Brink, R., Mackay, F., Hodgkin, P. D., & Tangye, S. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18025 · Cited by 509
Damage in systemic lupus erythematosus and its association with corticosteroids
Zonana-Nacach, A., Barr, S. G., Magder, L. S., & Petri, M. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1801::aid-anr16>3.0.co;2-o · Cited by 495
Self-citationNovel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationPetri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., Recta, V., Zhong, J., & Freimuth, W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23678 · Cited by 428
Self-citationJacobi, A. M., Odendahl, M., Reiter, K., Bruns, A., Burmester, G. R., Radbruch, A., Valet, G., Lipsky, P. E., & Dörner, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10949 · Cited by 361
An international cohort study of cancer in systemic lupus erythematosus
Bernatsky, S., Boivin, J. F., Joseph, L., Rajan, R., Zoma, A., Manzi, S., Ginzler, E., Urowitz, M., Gladman, D., Fortin, P. R., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21029 · Cited by 353
Self-citationThe role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Classification and definition of major flares in SLE clinical trials
Petri, M., Buyon, J., & Kim, M. (1999) · Lupus · doi:10.1191/096120399680411281 · Cited by 282
Self-citationB cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Guidelines for referral and management of systemic lupus erythematosus in adults
(1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199909)42:9<1785::aid-anr1>3.0.co;2-# · Cited by 269
Jacobi, A. M., Huang, W., Wang, T., Freimuth, W., Sanz, I., Furie, R., Mackay, M., Aranow, C., Diamond, B., & Davidson, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27189 · Cited by 243
Self-citationD'Cruz, D. P. (2006) · BMJ · doi:10.1136/bmj.332.7546.890 · Cited by 200
Treatment of lupus with corticosteroids
Chatham, W. W., & Kimberly, R. P. (2001) · Lupus · doi:10.1191/096120301675075008 · Cited by 177
Self-citationHalpern, W., Lappin, P. B., Zanardi, T. A., Cai, W., Corcoran, M. L., Zhong, J., & Baker, K. P. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj148 · Cited by 158
The socioeconomic burden of SLE
Lau, C. S., & Mak, A. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.106 · Cited by 137
Signalling crosstalk in B cells: managing worth and need
Cancro, M. P. (2009) · Nature reviews. Immunology · doi:10.1038/nri2621 · Cited by 124
From BILAG to BLIPS—disease activity assessment in lupus past, present and future
Isenberg, D. A., & Gordon, C. (2000) · Lupus · doi:10.1191/096120300672904669 · Cited by 109
The impact of flare on disease costs of patients with systemic lupus erythematosus
ZHU, T. Y., Tam, L., Lee, V. W. Y., Lee, K. K., & Li, E. K. (2009) · Arthritis Care & Research · doi:10.1002/art.24725 · Cited by 102
Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
Dörner, T. (2006) · PubMed · Cited by 85
Cited by
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Self-citationKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Self-citationTrial of Anifrolumab in Active Systemic Lupus Erythematosus
Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912196 · Cited by 1,379
Self-citationNew insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
Metadata
- Authors
- Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., Stohl, W., Ginzler, E. M., Hough, D. R., Zhong, Z. J., Freimuth, W., van Vollenhoven, R. F., & BLISS-76 Study Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-11-29
- Volume
- 63
- Issue
- 12
- Pages
- 3918-3930
- ISSN
- 0004-3591 (ISSN-L)
- OpenAlex
- W2136149088
- Cited by
- 1,683
- References
- 30
- FWCI
- 59.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.